GSK-1292263A

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGSK-1292263A
Drug Alias NameGSK-1292263AGSK-263AGSK-1292263
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucose-dependent insulinotropic receptor agonists
TargetsGlucose-dependent insulinotropic receptor
Therapy Area/IndicationsDyslipidemiasDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsDyslipidemiasDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A